Litcius/Paper detail

Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia

Joseph A. Fraietta, Simon F. Lacey, Elena J. Orlando, Iulian Pruteanu-Malinici, Mercy Gohil, Stefan Lundh, Alina C. Boesteanu, Yan Wang, Roddy S. O’Connor, Wei‐Ting Hwang, Edward Pequignot, David E Ambrose, Changfeng Zhang, Nicholas S. Wilcox, Felipe Bedoya, Corin L. Dorfmeier, Chen Fang, Lifeng Tian, Harit Parakandi, Minnal Gupta, Regina M. Young, F. Brad Johnson, Irina Kulikovskaya, Li Liu, Jun Xu, Sadik H. Kassim, Megan M. Davis, Bruce L. Levine, Noelle V. Frey, Donald L. Siegel, Alexander C. Huang, E. John Wherry, Hans Bitter, Jennifer L. Brogdon, David L. Porter, Carl H. June, J. Joseph Melenhorst

2018Nature Medicine1,774 citationsDOIOpen Access PDF

Topics & Concepts

Chimeric antigen receptorCD8ImmunologyChronic lymphocytic leukemiaAntigenCytotoxic T cellT cellCancer researchBiologyCD19Immune systemLeukemiaMedicineIn vitroBiochemistryCAR-T cell therapy researchImmune Cell Function and InteractionT-cell and B-cell Immunology
Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia | Litcius